Danaher gives upbeat guidance at JPMorgan healthcare conference
Danaher (DHR) upped its revenue guidance for the fourth quarter on January 8. The company is scheduled to report fourth quarter earnings on January 29. At the conference the company said that its core revenue growth for 2018 to date was 6%. Core operating margins were...
Adding yen exposure to Jubak Picks and Volatility Portfolios
On December 27 I switched to the Invesco Currency Shares Japanese Yen ETF (FXY) from the Vanguard FTSE Developed Markets ETF (VEA) in my Perfect 5 ETF Portfolio (on my subscription sites JugglingWithKnives.com and JubakAM.com) in an effort to get more yen exposure...
Pulling the plug on any significant end of the year rally: Selling small cap Russell 2000 ETF
Going into December, I thought there was enough chance of a strong end of the year rally/ January effect rally to make taking a risk on small company stocks a reasonable call. Even though the entire market looked shaky in the longer term. (That is in 2019.) With the...
My second global warming pick is Jubak Picks member Xylem
Xylem (XYL) One of the “ironies” (for lack of a better word) of Global Warming is that it will put lots of water where many people don’t want it, and it will leave many regions that have enough water now thirsty, and it will threaten to turn many existing supplies of...
Jubak Picks member Salesforce beats on earnings, raises guidance for 2019 and 2020
Salesforce (CRM) started today to the upside based on last night’s earnings beat of 11 cents a share. Salesforce shares were up 4.57% as of noon New York time today. And then came the market-wide bounce after Fed chair Jerome Powell’s speech suggesting...
Ionis Pharmaceuticals showing strong recovery on research pipeline, tweaking price target higher
It’s been a wild 2018 for Jubak Picks portfolio stock Ionis Pharmaceuticals (IONS.) Right now, though, the shares are on an upward trend. That’s likely to continue with the company looking at a strong research presentation at the December 1-4 meeting of...
Mixed news in Alibaba’s new Singles’ Day sales record
The 10th annual Singles’ Day sales frenzy on November 11 resulted in a new record at China’s Alibaba (BABA) for one-day sales of $213.5 billion yuan ($30.7 billion.) This year merchandise sales for the world’s largest off-line and on-line shopping...
Buying shares of small caps ETF for my Jubak Picks Portfolio today
In my Special Report “How to Protect Our Portfolio Without Selling Your Portfolio” (available to subscribers to my JubakAM.com site) I made the iShares Russell 2000 ETF (IWM) my third Portfolio Protection Pick. Today I’m adding it to my Jubak Picks...
Buy Salesforce My Newest Big Thing Stock for Jubak Picks Portfolio
My apologies that I didn’t get this post up last night but I had a short, strange, and very scary attack of vertigo at the end of my working day and missed that deadline. Everything seems to be fine today so here’s the post. When I added Salesforce.com...
Incyte news continues to rebuild credibility of pipeline
Shares of Incyte (INCY) climbed 2.51% today on the announcement of positive results from a Phase 2 clinical trial, GEOMETRY mono-1, evaluating MET inhibitor capmatinib in 94 adult patients with advanced non-small cell lung cancer. The company presented the data at...
Lions Gate Entertainment climbs again on Tuesday, October 2
Investors and traders are sure acting like they believe the Hollywood studio will be an acquisition target–soon–by one of the companies engaged in the heated battle to gain traction in the market for streaming media. The speculation right now points to...
Buying Tencent Holdings for my Jubak Picks Portfolio
Today (or tomorrow morning, actually, October 2) I’m adding Tencent Holdings (TCEHY) to my 12-18 month Jubak Picks Portfolio. (The stock is already a member of my long-term 50 Stocks Portfolio. As I wrote in my Special Report: 10 Picks for the Emerging Markets...
Do you have the patience for the Permian? Should you?
It hasn’t exactly been a great few months oil shale producers in the Permian Basin. Shares of Pioneer Natural Resources (PXD), the biggest pure play on Permian oil, closed at $169.97 a share today, August 29, down from $212.31 a share on May 18. That’s a...
Nektar beats on earnings–more importantly FDA accepts company’s new opioid for review
I wrote this post while on vacation in an effort to use this down time to catch up on earnings results that I missed during the very busy second quarter earning season. This post was written on August 18. After the market close on Wednesday, August 8,...
Incyte beats on revenue, misses on earnings; reports good progress in pipeline
I am on vacation until August 26. I am using that downtime to catch up on some of the earnings reports I missed during the very busy second quarter earnings season. On July 30 Incyte (INCY) reported second quarter earnings of 26 cents a share, 4 cents below the Wall...
Buying Albermarle today for my Jubak Picks Portfolio
Who says the collapse of the Turkish lira and of the Turkish stock market isn’t good news for anyone? While it’s certainly true that the troubles in Turkey–which have become worse as the country’s relationship with the United States has tipped...
Raising target price on Microsoft in Jubak Picks Portfolio after earnings
Going into yesterday’s earnings report from Microsoft, I felt torn. On the one hand, the stock had hit an all time record high on the strong guidance for the June quarter back in April. How much higher could the stock go? Would guidance for the September quarter...
One of my core beliefs after running the Jubak Picks portfolio for more than 20 years now is that when the reason I picked a stock to buy evaporates, then it’s time to sell. So today (June 21) I’m selling Starbucks (SBUX) out of my Jubak Picks portfolio....
Selling MGM Resorts on escalating China trade war fears
I still believe in all the catalysts that I touted for MGM Resorts International (MGM) for late this year–yes, the company’s new Macao casino will give the company more exposure to that market, yes, a wave of states legalizing sports gambling plays to...
Adding Microsoft to my Jubak Picks portfolio–hoping for a July “miss” like that in April
As I wrote in Part 3 of my Special Report “Investing in a Late Cycle Market,” (available to subscribers to my paid JubakAM.com site), I’m adding Microsoft to my Jubak Picks portfolio. The April third quarter earnings “miss” sets Microsoft...
Nektar up 6.32% today on opioid data presentation
Frankly, my holdings of shares and options on Nektar Therapeutics (NKTR) are driving me nuts. The stock is just so volatile that I can barely stand it even though I’m comfortable with the long-term trajectory of the company’s new non-addictive opioid and...
AT&T acquisition of Time Warner clears courts–let the media frenzy begin (and here’s what I’d buy)
Yesterday after the close of trading Judge Richard Leon gave the go-ahead to AT&T’s (T) acquisition of Time Warner, the owner of HBO and other content. The ruling is a green light to other vertical mergers in the media sector. The judge rejected the...
Time to further lighten up on emerging markets: Selling Arcos Dorados out of Jubak Picks
Back when emerging markets started to break down, I sold my positions in Argentina. Then it looked like the damage might be limited to that country. Not though it’s clear that the whole sector is under pressure and that investors trying to avoid the next...
Nektar’s 40% drop yesterday was an extreme over-reaction: What I’m doing now
It’s never good to turn in disappointing results in a drug trial–as Nektar Therapeutics (NKTR) did over the weekend–but to whack 40% off the stock price on this news is an extreme over-reaction. To justify a 40% drop you have to assume 1) that the...
FDA delivers less than half a loaf to INCY and LLY in approving Olumiant
Today the U.S. Food & Drug Administration did finally approve Baricitinib, now known as Olumiant, for the treatment of moderately-to-severely active rheumatoid arthritis. But the approval carries more restrictions than expected. The FDA approved only the 2...
Book keeping changes: Statoil (STO) changes its name and ticker to Equinor (EQNR)
A change in the name and ticker of portfolio holding Statoil (STO). The explanation offered by the company is that it wanted to remove “oil” from its name to better reflect the company’s increasing emphasis on other forms of energy including wind...
Adding shares of Valero Energy to my Jubak Picks Portfolio
Last night on my JubakAM.com and JugglingWithKnives.com subscription sites I laid out the case argued by Morgan Stanley for believing that distillate prices are heading higher in the face of a tight supplies for these refinery products. One of the refiners Morgan...
Stock or options, Nektar needs some understanding and patience now
It hasn’t exactly been a stellar couple of months for shares and options on Nektar Therapeutics (NKTR). The stock, which I hold in my Jubak Picks portfolio, is down 23.1% since it hit a high of $108.44 on March 8. The August 17, 2018 call options with a strike...
Nvidia crushes earnings; stock falls after hours
Okay, if you’re a trader I sort of understand selling Nvidia (NVDA) after today’s earnings report: Sell on the news; How can it get better? How long can the company keep it up? After all, the stock closed today just pennies below it’s all time high....Jim’s Daily Email Alerts:
Every post from Jubak Picks straight to your mailbox. And they're free!